These results support the concept that the anti-PD-1–GITR-L bispecific can potentially synergize with other immunotherapies (that is, anti-TIGIT antibodies, CAR T cells, immunocytokines and so on) in immunogenically cold cancer indications. Here, PDCD1 is linked to cancer.